Patents Assigned to PepMab B.V.
-
Publication number: 20220135693Abstract: The present invention provides novel humanized anti-human CCR7 antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.Type: ApplicationFiled: January 18, 2022Publication date: May 5, 2022Applicant: PepMab B.V.Inventors: Jaap Willem Back, Ronald Boshuizen, Wouter Cornelis Puijk, Johan Turkstra, Klaus Heinrich Schwamborn
-
Patent number: 11254749Abstract: The present invention provides novel humanized anti-human C—C chemokine receptor type 7 (CCR7) antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.Type: GrantFiled: March 10, 2020Date of Patent: February 22, 2022Assignee: PepMab B.V.Inventors: Jaap Willem Back, Ronald Boshuizen, Wouter Cornelis Puijk, Johan Turkstra, Klaus Heinrich Schwamborn
-
Publication number: 20200362043Abstract: The present invention provides novel humanized anti-human CCR7 antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.Type: ApplicationFiled: March 10, 2020Publication date: November 19, 2020Applicant: PepMab B.V.Inventors: Jaap Willem Back, Ronald Boshuizen, Wouter Cornelis Puijk, Johan Turkstra, Klaus Heinrich Schwamborn
-
Patent number: 10640565Abstract: The present invention provides novel humanized anti-human C-C chemokine receptor type 7 (CCR7) antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.Type: GrantFiled: August 10, 2016Date of Patent: May 5, 2020Assignee: PepMab B.V.Inventors: Jaap Willem Back, Ronald Boshuizen, Wouter Cornelis Puijk, Johan Turkstra, Klaus Heinrich Schwamborn
-
Publication number: 20180237529Abstract: The present invention provides novel humanized anti-human CCR7 antibodies and compositions comprising such antibodies. The antibodies and compositions are useful in the treatment of a cancer of which the tumour cells express a CCR7 receptor, in the treatment of inflammatory conditions, conditions or complications arising from tissue or organ transplantations, and conditions or complications arising from or associated with fibrosis. The invention further provides nucleic acid molecules encoding the anti-CCR7 antibodies, cells expressing the anti-CCR7 antibodies and methods for producing the anti-CCR7 antibodies.Type: ApplicationFiled: August 10, 2016Publication date: August 23, 2018Applicant: PepMab B.V.Inventors: Jaap Willem Back, Ronald Boshuizen, Wouter Cornelis Puijk, Johan Turkstra